Eloxx Pharmaceuticals Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$74.2M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Eloxx Pharmaceuticals's estimated annual revenue is currently $3.3M per year.(i)
  • Eloxx Pharmaceuticals's estimated revenue per employee is $116,250
  • Eloxx Pharmaceuticals's total funding is $74.2M.

Employee Data

  • Eloxx Pharmaceuticals has 28 Employees.(i)
  • Eloxx Pharmaceuticals grew their employee count by -15% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-99%N/AN/A
#2
$3.1M20233%N/AN/A
#3
$21.5M13918%$351MN/A
#4
$18M1165%$312.8MN/A
#5
$235M418-23%$340.9MN/A
#6
$2.2M3417%N/AN/A
#7
$6M40-9%$176.5MN/A
#8
$109.4M70614%N/AN/A
#9
$6.2M40233%N/AN/A
#10
$1.9M12-20%N/AN/A

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx's lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.

keywords:N/A

$74.2M

Total Funding

28

Number of Employees

$3.3M

Revenue (est)

-15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Eloxx Pharmaceuticals News

2022-04-20 - Where Does Wall Street Think Eloxx Pharmaceuticals Inc (ELOX) Stock Will Go?

Where Does Wall Street Think Eloxx Pharmaceuticals Inc (ELOX) Stock Will Go? Thursday, April 21, 2022 12:04 PM | InvestorsObserver Analysts.

2022-04-20 - Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Given Average ...

Eloxx Pharmaceuticals, Inc engages in the development of novel ribonucleic acid-modulating drug candidates. The firm focuses on the the...

2022-03-30 - Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial ...

Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging its innovative TURBO-ZMTM chemistry technology platform...

2021-10-05 - Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital

Eloxx Pharmaceuticals, Inc. announced that the company has entered into a debt facility of up to $30.0 million with Hercules Capital, Inc. Eloxx has drawn the initial tranche of $12.5 million and used the proceeds to repay in full amounts outstanding under the company’s existing debt facility. T ...

2021-10-05 - Hercules Capital : Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital

WATERTOWN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the company has entered into a debt facility of up to $30.0 million with Hercules Capital, Inc. (NYSE: HTGC), a specialty financing lender for life science and technology companie ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.1M28N/AN/A
#2
$2.8M2817%N/A
#3
$5.3M28-12%N/A
#4
$4.3M284%N/A
#5
$2.9M290%N/A